Aberrant co-expression of CD19 and CD56 as surrogate markers of acute myeloid leukemias with t(8;21) in Taiwan

International Journal of Laboratory Hematology

Volumn 30, Issue 2, 2008, Pages 133-138

  Chen, S W ^a   Li, C F ^b   Chuang, S S ^b,c,f   Tzeng, C C ^b   Hsieh, Y C ^b   Lee, P S ^d   Chen, C H ^a   Huang, W T ^a   Hwang, W S ^e   Tsao, C J ^a  

^a CHI MEI FOUNDATION HOSPITAL   (Taiwan)

^b CHI MEI FOUNDATION HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d Genzyme Genetics ^*  (United States)

^e CHI MEI MEDICAL CENTER   (Taiwan)

^f Chi Mei Foundation Hospital   (Taiwan)

Author keywords

Acute myeloid leukemia; CD19; CD56; Flow cytometry; T(8; 21)

Indexed keywords

CD19 ANTIGEN; CD2 ANTIGEN; CD22 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; RETROSPECTIVE STUDY; TAIWAN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD56; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAIWAN; TRANSLOCATION, GENETIC;

EID: 40549144886     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2007.00913.x     Document Type: Article

References (18)

1. Baer M.R., Stewart C.C., Lawrence D., Arthur D.C., Byrd J.C., Davey F.R., Schiffer C.A. Bloomfield C.D. (1997) Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 90, 1643 1648.
2. Bene M.C., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Orfao A. van't Veer M.B. (1995) Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9, 1783 1786.
3. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R. Sultan C. (1985) Proposed revised criteria for the classification of acute myeloid leukemias. A report of the French-American-British Cooperative Group. Annals of Internal Medicine 103, 620 625.
4. Bona E.D., Sartori R., Zambello R., Guercini N., Madeo D. Rodeghiero F. (2002) Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica 87, 250 256.
5. Cunningham B.A., Hemperly J.J., Murray B.A., Prediger E.A., Brackenbury R. Edelman G.M. (1987) Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science 236, 799 806.
6. Del Poeta G., Stasi R., Venditti A., Suppo G., Aronica G., Bruno A., Masi M., Tabilio A. Papa G. (1994) Prognostic value of cell maker analysis in de novo acute myeloid leukemia. Leukemia 8, 388 394.
7. Drexler H.G., Thiel E. Ludwig W.D. (1993) Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance. Leukemia 7, 489 498.
8. Ferrara F., Morabito F., Martino B., Specchia G., Liso V., Nobile F., Boccuni P., Di Noto R., Pane F., Annunziata M., Schiavone E.M., De Simone M., Guglielmi C., Del Vecchio L. Lo Coco F. (2000) CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. Journal of Clinical Oncology 18, 1295 1300.
9. Hsiao C.H., Tang J.L., Yao M., Tsay W., Wang C.H., Chen Y.C., Shen M.C. Tien H.F. (2002) High incidence of CD56 expression and relapse rate in acute myeloid leukemia patients with t(8;21) in Taiwan. Journal of the Formosan Medical Association 101, 393 398.
10. Hurwitz C.A., Raimondi S.C., Head D., Krance R., Mirro J. Jr., Kalwinsky D.K., Ayers G.D. Behm F.G. (1992) Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 80, 3182 3188.
11. Kaleem Z., Crawford E., Pathan M.H., Jasper L., Covinsky M.A., Johnson L.R. White G. (2003) Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Archives of Pathology and Laboratory Medicine 127, 42 48.
12. Khoury H., Dalal B.I., Nevill T.J., Horsman D.E., Barnett M.J., Shepherd J.D., Toze C.L., Conneally E.A., Sutherland H.J., Hogge D.E. Nantel S.H. (2003) Acute myelogenous leukemia with t(8;21)-identification of a specific immunophenotype. Leukemia and Lymphoma 44, 1713 1718.
13. Kita K., Shirakawa S. Kamada N. (1994) Cellular characterstics of acute myeloblastic leukemia associated with t(8;21)(q22;q22). Leukemia and Lymphoma 13, 229 234.
14. Mitelman F. (1995) An International System for Human Cytogenetic Nomenclature. S. Karger, Basel, Switzerland.
15. Rege K., Swansbury G.J., Atra A.A., Horton C., Min T., Dainton M.G., Matutes E., Durosinmi M., Treleaven J.G., Powles R.L. Catovsky D. (2000) Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leukemia and Lymphoma 40, 67 77.
16. Saxena A., Sheridan D.P., Card R.T., McPeek A.M., Mewdell C.C. Skinnider L.F. (1998) Biologic and clinical significance of CD7 expression in acute myeloid leukemia. American Journal of Hematology 58, 278 284.
17. Seymour J.F., Pierce S.A., Kantarjian H.M., Keating M.J. Estey E.H. (1994) Investigation of karyotypic, morphologic and clinical features inpatients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 8, 823 826.
18. Tien H.F., Wang C.H., Chen Y.C., Shen M.C., Lin D.T. Lin K.H. (1993) Characterization of acute myeloid leukemia (AML) coexpressing lymphoid makers: different biologic features between T-cell antigen positive and B-cell antigen positive AML. Leukemia 7, 688 895.